This invention belongs to the field of
biomedical technology, specifically relating to a method for constructing a highly
cell-adaptive PEDV GIIc recombinant
chimeric virus. Specifically, this invention, based on the PEDV viral S
protein determining PEDV'
s cell adaptability, innovatively elucidates that S2 is the key
subunit determining its
cell adaptability. On this basis, this invention proposes a scheme that can increase viral
titer and thus reduce
vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2
subunit of the highly
cell-adaptive strain and replacing the S1
subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the
immunogenicity of the circulating strain and improve the efficiency of high-
titer vaccine production.